Blood thinner study targets obesity and surgery gaps
NCT ID NCT04180436
First seen Jan 09, 2026 · Last updated Apr 25, 2026 · Updated 17 times
Summary
This study looked at how the blood thinner rivaroxaban behaves in people with severe obesity and in those who had weight-loss surgery (gastric bypass or sleeve gastrectomy). Sixty-seven participants took rivaroxaban for 8 days, and researchers measured drug levels and clotting effects. The goal was to understand if obesity or surgery changes how the drug works, which can help doctors prescribe safer doses.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for MORBID OBESITY are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
CHRU de Brest
Brest, France, 29609, France
Conditions
Explore the condition pages connected to this study.